FATP2 plays a crucial role in regulating lipid accumulation-induced oxygen species in MDSCs, and targeting FATP2 in MDSCs can serve as a novel therapeutic method to enhance anti-PD-L1 cancer immunotherapy [184]. Here, SLC27A2 is linked to cancer.